Recro Pharma announced several key promotions to its executive leadership team. Michael Celano has been promoted to Chief Operating Officer, and Ryan D. Lake has been promoted to Chief Financial Officer.
“I am pleased to announce the promotions of Mike and Ryan, two critical members of our financial leadership team,” said Gerri Henwood, president and chief executive officer of Recro Pharma. “With the sustained, strong performance and significant contribution of the contract development and manufacturing (CDMO) facility to Recro, as well as the active pre-commercialization efforts for IV meloxicam 30mg in anticipation of launch following the potential approval by the U.S. Food and Drug Administration (FDA) next year, it is imperative that we have a strong and skilled team in place capable of executing across both divisions of Recro.”
Mr. Celano has over 35 years of senior financial leadership experience in the life sciences and biopharmaceutical industries, and joined Recro in July 2016 as Chief Financial Officer. Mr. Lake joined Recro in June 2017 as the Company’s Chief Accounting Officer, and he has over 15 years of senior financial leadership experience. Prior to joining Recro, Mr. Lake served as Chief Financial Officer and Vice President of Finance of Aspire Bariatrics, Inc., a privately-held, commercial-stage, medical device company.